Document Detail

Critical role of mTOR in calcineurin inhibitor-induced renal cancer progression.
MedLine Citation:
PMID:  22293493     Owner:  NLM     Status:  MEDLINE    
Aninda Basu; Pallavi Banerjee; Soumitro Pal
Related Documents :
17429393 - Mediators of vascular remodelling co-opted for sequential steps in lung metastasis.
11340043 - Effects of drought stress and high density stem inoculations with leptographium wingfie...
7712653 - Bloom's syndrome.
Publication Detail:
Type:  Editorial; Research Support, N.I.H., Extramural     Date:  2012-02-15
Journal Detail:
Title:  Cell cycle (Georgetown, Tex.)     Volume:  11     ISSN:  1551-4005     ISO Abbreviation:  Cell Cycle     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-29     Completed Date:  2012-09-14     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  101137841     Medline TA:  Cell Cycle     Country:  United States    
Other Details:
Languages:  eng     Pagination:  633-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcineurin / antagonists & inhibitors*
Immunosuppressive Agents / adverse effects*,  therapeutic use
Kidney Neoplasms / chemically induced*,  genetics,  metabolism*
TOR Serine-Threonine Kinases / genetics,  metabolism*
Grant Support
R01 CA131145/CA/NCI NIH HHS; R01 CA131145/CA/NCI NIH HHS; R01 CA131145-03/CA/NCI NIH HHS
Reg. No./Substance:
0/Immunosuppressive Agents; EC Serine-Threonine Kinases; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New Flavan and Benzil Isolated from Fissistigma latifolium.
Next Document:  The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.